Literature DB >> 25463639

An odyssey through salpingitis isthmica nodosa.

Ibrahim I Bolaji1, Monika Oktaba2, Kevin Mohee2, Ka Yan Shirley Sze2.   

Abstract

Salpingitis isthmica nodosa (SIN) is a nodular swelling of the isthmic segment of the fallopian tube. It is of unknown aetiology and is usually an acquired pathologic condition resulting from direct invasion of the muscularis layer by the endosalpinx in the isthmic portion of the fallopian tube between the lumen and the serosa. The clinical significance of SIN rests on its strong association with tubal ectopic pregnancy and subfertility. Assisted reproductive technology (ART) has improved the reproductive capability of SIN patients. Unlike ART, which bypasses pelvic pathologies, tubal surgical approaches improve fertility by correcting the pathology and can improve a patient's related symptoms of pelvic pain and abnormal menstruation, and provide a permanent cure. This paper gives an update on the epidemiology, aetiology, diagnosis and management of SIN and concludes that despite the reported successes with tubal surgery, the mainstay of treatment remains ART in (in the UK) centres recognised by the Human Fertilization and Embryology Authority (HFEA). The success of surgical infertility therapy depends on careful selection of cases using appropriate investigative techniques, with the procedures carried out in centres with sufficient expertise.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Assisted reproductive technology; Ectopic pregnancy; Infertility; Pelvic inflammatory disease; Salpingitis isthmica nodosa; Tubal surgery

Mesh:

Year:  2014        PMID: 25463639     DOI: 10.1016/j.ejogrb.2014.11.014

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  1 in total

1.  Salpingitis Impairs Bovine Tubal Function and Sperm-Oviduct Interaction.

Authors:  Loveth E Owhor; Sven Reese; Sabine Kölle
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.